About US
Contact us
-
Indian sales reps strike to demand strict drug-promo rulesIn the U.S., pharma sales reps turn whistleblower when they believe their companies are flouting the rules. In India, they apparently go on strike. According to domestic media reports, about 150,2012/8/24
-
Pfizer figures traditional drug promos are getting oldNo question that the viewing public has grown cynical about drug advertising. Who hasn't mocked the stock-in-trade DTC ad? Its smiling patients and grinning animated figures, backed up by a litany o2012/8/24
-
Ex-rep claims Abbott pushed TriCor off-labelAbbott Laboratories ($ABT) recently wrapped up its Depakote difficulties with the Department of Justice, with a $1.6 billion off-label marketing settlement. Now, we discover that another Abbott ex-e2012/8/23
-
Wockhardt to sell generic copy of Pfizer’s Geodon in IndiaIndia-based drug maker Wockhardt has received tentative approval to market its generic version of Geodon (ziprasidone), an anti-psychotic drug sold in the US by Pfizer. The US Food and Drug Administr2012/8/23
-
Sanofi crowdsources tweaks to social media strategySocial media may be a potential minefield for Big Pharma, but some companies are finding their way safely. One of them is Sanofi ($SNY), which recovered from a Facebook slap from a disgruntled patie2012/8/22
-
GSK to buy in APIs rather than keep Indian plant runningGlaxoSmithKline ($GSK) will turn to outsourcing to replace APIs made at an Indian plant on its way to closure. Rather than sink more capital into improving the Thane, India, plant, the company will2012/8/22
-
Drug Safety Blacklist Management Rules (interim) to be implemented on October 1The State Food and Drug Administration issued the Drug Safety Blacklist Management Rules (interim) on August 14, 2012. According to the Management Rules, relevant information of producers, operators a2012/8/21
-
Predictions for emerging markets hit new realitiesFor several years now, Eli Lilly ($LLY) has been telling shareholders that China would pay off big time for the drugmaker. Its plan was to be the fastest-growing company in Big Pharma, reaping sales f2012/8/21
-
Novartis, India face off over patent-protection future thereIt is the moment of truth for Novartis ($NVS) and its widely watched patent fight with India. But while this case is over its groundbreaking cancer treatment Gleevec, it will define what kind of intel2012/8/21
-
Roche runs short on Boniva after overestimating generic erosionMany companies have been caught off-guard by the extent to which generic competition has eaten away at their sales. Genentech says it managed to be caught by surprise, however, by a lack thereof; lead2012/8/20